Quick Answer
An introduction to CAR-T therapy, from eligibility to cytokine release syndrome and follow-up.
Medically reviewed by Dr. Sachita Baniya • NMC 20158 • Kathmandu Neurology Clinic & Cognitive Center
CAR-T cell therapy is a type of cellular immunotherapy. A patient's T cells are collected, genetically modified to recognise a specific protein on cancer cells, and returned after a short course of lymphodepleting chemotherapy. It is used in selected relapsed or refractory blood cancers.
How it works
The engineered T cells carry a chimeric antigen receptor (CAR) that binds a target antigen on the cancer cell. When the CAR-T cells encounter the target, they activate and kill the cancer cell. They can also persist in the body and provide ongoing surveillance.
Who may be eligible
- Selected relapsed or refractory B-cell lymphomas
- Selected relapsed or refractory B-ALL
- Selected relapsed or refractory multiple myeloma
- Adequate organ function and performance status
- Access to a cellular therapy centre
Eligibility depends on the disease subtype, antigen expression, prior treatments and the treating centre's programme. Referral should be discussed early enough to allow collection, manufacturing and bridging therapy.
What the treatment involves
After collection, the cells are manufactured, which takes time. Lymphodepleting chemotherapy is given before infusion. Patients are monitored closely for at least the first few weeks.
Side effects
Cytokine release syndrome can cause fever, low blood pressure, breathlessness and organ dysfunction. Neurological toxicity can cause confusion, seizures, speech change or weakness. Both require prompt grading and treatment. Infection and low blood counts can persist after discharge.
Follow-up
Long-term follow-up includes blood counts, disease assessment and monitoring for infection. Some patients achieve durable remissions; others relapse. The team discusses expectations individually.
The bottom line
CAR-T is an important option for selected patients, but it is not a simple treatment. Understanding the timeline, the risks and the need for close monitoring helps patients and families prepare.
Frequently asked questions
Answers reviewed by Dr. Jitendra Prasad Yadav • MBBS, MD (Internal Medicine), FICN (Neurology), FCNV, FIHM • NMC 8029
DLBCL is potentially curable with first-line chemoimmunotherapy in a substantial proportion of patients. Prognosis depends on stage, biology, response and fitness.
R-CHOP is a combination of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone. Variants and newer regimens are used for specific subtypes or risk groups.
Yes, ALL is the most common childhood cancer, but it also occurs in adults. Adult ALL often requires more intensive support and has a higher risk of relapse, so transplant assessment is more frequently considered.
ALL treatment includes several phases designed to clear leukemia, prevent CNS relapse and eliminate residual disease. Maintenance therapy can continue for months to years, with regular monitoring.
More: All FAQs → · Ask Dr. Jitendra →
Related articles
Measurable Residual Disease: Why 'No Blasts Seen' Is Not Always Remission
MRD testing can detect cancer cells below the limit of microscopy. Learn how it guides treatment in leukemia and myeloma.
Lymphoma: Symptoms, Biopsy and What Comes Next
Lymphoma often starts with a painless swollen lymph node. Learn how the diagnosis is made and why the biopsy matters.
Molecular Testing in Blood Cancer: What the Results Mean
Cytogenetics, FISH, PCR and next-generation sequencing guide diagnosis, risk and treatment in blood cancers.
Medical Disclaimer
Content on this website is for general educational purposes only and does not constitute medical advice, diagnosis, or treatment. It is not a substitute for evaluation by a qualified healthcare professional. Always seek the advice of your physician or other qualified provider with any questions regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read on this website. In case of a medical emergency, contact emergency services immediately. No doctor–patient relationship is established by use of this site or by contacting the clinic through the site.
References & Review
Reviewed by Dr. Jitendra Prasad Yadav • Last reviewed: 2026-11-10
- International Classification of Headache Disorders, 3rd edition (ICHD-3).
- Harrison's Principles of Internal Medicine — Neurology sections.
- American Academy of Neurology guidelines for selected conditions (where applicable).
Content is educational and aligns with standard medical references; individual evaluation may vary. External links provide context and do not imply endorsement.